{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:16:30Z","timestamp":1780427790886,"version":"3.54.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13318-025-00967-y","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T07:57:00Z","timestamp":1758959820000},"page":"461-477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic Implications of Pathophysiological Changes in Cachexia Syndrome: A Scoping Review"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0612-3354","authenticated-orcid":false,"given":"Safeer","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-7164","authenticated-orcid":false,"given":"Muhammad Nasir","family":"Kalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik Hassan","family":"Mehmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman Rashid","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Muhammad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"967_CR1","doi-asserted-by":"publisher","first-page":"1252030","DOI":"10.3389\/fphar.2023.1252030","volume":"14","author":"A Khan","year":"2023","unstructured":"Khan A, et al. The practical implication of clinical pharmacokinetics in drug development, pharmaceutical analysis, and clinical research. Front Pharmacol. 2023;14:1252030.","journal-title":"Front Pharmacol"},{"issue":"1","key":"967_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jps.22253","volume":"100","author":"JY Chien","year":"2011","unstructured":"Chien JY, Ho RJ. Drug delivery trends in clinical trials and translational medicine: evaluation of pharmacokinetic properties in special populations. J Pharm Sci. 2011;100(1):53\u20138.","journal-title":"J Pharm Sci"},{"issue":"1","key":"967_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03602532.2018.1508226","volume":"51","author":"S Khan","year":"2019","unstructured":"Khan S, Shahzadi A. Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review. Drug Metab Rev. 2019;51(1):1\u201311.","journal-title":"Drug Metab Rev"},{"issue":"10","key":"967_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.cmi.2015.05.002","volume":"21","author":"F Sime","year":"2015","unstructured":"Sime F, Roberts M, Roberts J. Optimization of dosing regimens and dosing in special populations. Clin Microbiol Infect. 2015;21(10):886\u201393.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"967_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079603","volume":"8","author":"K Trobec","year":"2013","unstructured":"Trobec K, et al. Pharmacokinetics of drugs in cachectic patients: a systematic review. PLoS ONE. 2013;8(11):e79603.","journal-title":"PLoS ONE"},{"issue":"6","key":"967_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793\u20139.","journal-title":"Clin Nutr"},{"key":"967_CR7","doi-asserted-by":"publisher","first-page":"112301","DOI":"10.1016\/j.nut.2023.112301","volume":"119","author":"J Ueshima","year":"2023","unstructured":"Ueshima J, et al. Diagnosis and prevalence of cachexia in Asians: a scoping review. Nutrition. 2023;119:112301.","journal-title":"Nutrition"},{"key":"967_CR8","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S334228","author":"J De Brandt","year":"2022","unstructured":"De Brandt J, et al. Update on the etiology, assessment, and management of COPD cachexia: considerations for the clinician. Int J Chron Obstruct Pulmon Dis. 2022. https:\/\/doi.org\/10.2147\/COPD.S334228.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"967_CR9","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/jcsm.12603","volume":"11","author":"S von Haehling","year":"2020","unstructured":"von Haehling S, et al. Muscle wasting as an independent predictor of survival in patients with chronic heart failure. J Cachexia Sarcopenia Muscle. 2020;11(5):1242\u20139.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"967_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/182872","volume":"2015","author":"JM Argil\u00e9s","year":"2015","unstructured":"Argil\u00e9s JM, et al. Nonmuscle tissues contribution to cancer cachexia. Mediat Inflamm. 2015;2015(1):182872.","journal-title":"Mediat Inflamm"},{"issue":"9","key":"967_CR11","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","volume":"186","author":"M Ferrer","year":"2023","unstructured":"Ferrer M, et al. Cachexia: a systemic consequence of progressive, unresolved disease. Cell. 2023;186(9):1824\u201345.","journal-title":"Cell"},{"issue":"1","key":"967_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/jcsm.12012","volume":"6","author":"K Cvan Trobec","year":"2015","unstructured":"Cvan Trobec K, et al. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle. 2015;6(1):45\u201352.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"967_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"1","key":"967_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.pain.2009.04.012","volume":"144","author":"T Heiskanen","year":"2009","unstructured":"Heiskanen T, et al. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1):218\u201322.","journal-title":"Pain"},{"issue":"e2","key":"967_CR15","doi-asserted-by":"publisher","first-page":"E184","DOI":"10.1136\/bmjspcare-2019-001935","volume":"12","author":"SA Alsirafy","year":"2022","unstructured":"Alsirafy SA, et al. Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia. BMJ Support Palliat Care. 2022;12(e2):E184\u20136.","journal-title":"BMJ Support Palliat Care"},{"issue":"1","key":"967_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1078155220929415","volume":"27","author":"LD Jackson","year":"2021","unstructured":"Jackson LD, et al. Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: a case report and review of the literature. J Oncol Pharm Pract. 2021;27(1):238\u201343.","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"967_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/bmjspcare-2018-001652","volume":"9","author":"D Lam","year":"2019","unstructured":"Lam D, et al. Unusual case of transdermal fentanyl in cachexia. BMJ Support Palliat Care. 2019;9(4):363\u20134.","journal-title":"BMJ Support Palliat Care"},{"issue":"26","key":"967_CR18","doi-asserted-by":"publisher","first-page":"18224","DOI":"10.18632\/oncotarget.24804","volume":"9","author":"LB Bindels","year":"2018","unstructured":"Bindels LB, et al. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. Oncotarget. 2018;9(26):18224\u201338.","journal-title":"Oncotarget"},{"issue":"6","key":"967_CR19","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1002\/jcsm.12798","volume":"12","author":"L Feng","year":"2021","unstructured":"Feng L, et al. Bile acid metabolism dysregulation associates with cancer cachexia: roles of liver and gut microbiome. J Cachexia Sarcopenia Muscle. 2021;12(6):1553\u201369.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"7","key":"967_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.5483\/BMBRep.2023-0068","volume":"56","author":"SM Jeong","year":"2023","unstructured":"Jeong SM, et al. The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model. BMB Rep. 2023;56(7):404.","journal-title":"BMB Rep"},{"key":"967_CR21","doi-asserted-by":"publisher","first-page":"106332","DOI":"10.1016\/j.micpath.2023.106332","volume":"183","author":"H Liu","year":"2023","unstructured":"Liu H, et al. Unraveling the gut microbiota and short-chain fatty acids characteristics and associations in a cancer cachexia mouse model. Microb Pathog. 2023;183:106332.","journal-title":"Microb Pathog"},{"key":"967_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30569-5","author":"SA P\u00f6tgens","year":"2018","unstructured":"P\u00f6tgens SA, et al. Klebsiella oxytoca expands in cancer cachexia and acts as a gut pathobiont contributing to intestinal dysfunction. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-30569-5.","journal-title":"Sci Rep"},{"issue":"2","key":"967_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/jcsm.12684","volume":"12","author":"SA P\u00f6tgens","year":"2021","unstructured":"P\u00f6tgens SA, et al. Multi-compartment metabolomics and metagenomics reveal major hepatic and intestinal disturbances in cancer cachectic mice. J Cachexia Sarcopenia Muscle. 2021;12(2):456\u201375.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"967_CR24","first-page":"759","volume":"12","author":"B Yu","year":"2019","unstructured":"Yu B, et al. Abnormality of intestinal cholesterol absorption in Apc(Min\/+) mice with colon cancer cachexia. Int J Clin Exp Pathol. 2019;12(3):759\u201367.","journal-title":"Int J Clin Exp Pathol"},{"issue":"6","key":"967_CR25","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0899-9007(98)00038-0","volume":"14","author":"WT Chance","year":"1998","unstructured":"Chance WT, et al. Reduction of gut hypoplasia and cachexia in tumor-bearing rats maintained on total parenteral nutrition and treated with peptide YY and clenbuterol. Nutrition. 1998;14(6):502\u20137.","journal-title":"Nutrition"},{"issue":"5","key":"967_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00418-012-0995-3","volume":"138","author":"T Graulich","year":"2012","unstructured":"Graulich T, et al. Cancer cachexia alters intracellular surfactant metabolism but not total alveolar surface area. Histochem Cell Biol. 2012;138(5):803\u201313.","journal-title":"Histochem Cell Biol"},{"issue":"4","key":"967_CR27","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0002-9149(98)00927-8","volume":"83","author":"SD Anker","year":"1999","unstructured":"Anker SD, et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol. 1999;83(4):612\u20135 (a10).","journal-title":"Am J Cardiol"},{"issue":"21","key":"967_CR28","doi-asserted-by":"publisher","first-page":"6379","DOI":"10.1158\/1078-0432.CCR-07-1147","volume":"13","author":"M Fouladiun","year":"2007","unstructured":"Fouladiun M, et al. Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia. Clin Cancer Res. 2007;13(21):6379\u201385.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"967_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111934","volume":"42","author":"FA Graca","year":"2023","unstructured":"Graca FA, et al. Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice. Cell Rep. 2023;42(1):111934.","journal-title":"Cell Rep"},{"key":"967_CR30","first-page":"679","volume":"7","author":"A Bonetto","year":"2016","unstructured":"Bonetto A, et al. Differential bone loss in mouse models of colon cancer cachexia. Front Physiol. 2016;7:679.","journal-title":"Front Physiol"},{"key":"967_CR31","first-page":"727","volume":"145","author":"W Doehner","year":"2001","unstructured":"Doehner W, et al. Hyperleptinaemia in chronic heart failure relates to growth hormone binding protein in male patients with and without cardiac cachexia. Eur Heart J. 2001;145:727\u201335.","journal-title":"Eur Heart J"},{"issue":"1","key":"967_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.metabol.2013.09.017","volume":"63","author":"HM Christensen","year":"2014","unstructured":"Christensen HM, et al. Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study. Metabolism. 2014;63(1):141\u20139.","journal-title":"Metabolism"},{"issue":"9","key":"967_CR33","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00330-015-3692-5","volume":"25","author":"RD Boutin","year":"2015","unstructured":"Boutin RD, et al. MRI findings of serous atrophy of bone marrow and associated complications. Eur Radiol. 2015;25(9):2771\u20138.","journal-title":"Eur Radiol"},{"issue":"5","key":"967_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/bjh.14795","volume":"178","author":"N Chan","year":"2017","unstructured":"Chan N, Ho C, Yip SF. Cardiac cachexia causing extensive serous degeneration of bone marrow. Br J Haematol. 2017;178(5):660.","journal-title":"Br J Haematol"},{"issue":"6","key":"967_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/phy2.144","volume":"1","author":"E Choi","year":"2013","unstructured":"Choi E, et al. Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep. 2013;1(6):e00144.","journal-title":"Physiol Rep"},{"issue":"2","key":"967_CR36","first-page":"363","volume":"21","author":"ME Martignoni","year":"2009","unstructured":"Martignoni ME, et al. Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol Rep. 2009;21(2):363\u20139.","journal-title":"Oncol Rep"},{"key":"967_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061194","author":"JW Meyer-Knees","year":"2024","unstructured":"Meyer-Knees JW, et al. Cachexia-affected survival based on inflammatory parameters compared to complex conventional nutritional assessments in patients with pancreatic cancer and other gastrointestinal tumors\u2014the CONKO 020 investigation. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16061194.","journal-title":"Cancers"},{"issue":"6","key":"967_CR38","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00280-023-04537-4","volume":"91","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, et al. Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients. Cancer Chemother Pharmacol. 2023;91(6):481\u201390.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"967_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00280-005-0012-9","volume":"57","author":"JD Herrington","year":"2006","unstructured":"Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI > or = 27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"967_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2022.111711","volume":"102","author":"X-R Li","year":"2022","unstructured":"Li X-R, et al. Association of serum total bilirubin with survival outcomes in patients with cancer cachexia: a prospective, multicenter cohort study. Nutrition. 2022;102:111711.","journal-title":"Nutrition"},{"issue":"5","key":"967_CR41","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/jcsm.12449","volume":"10","author":"RGF Costa","year":"2019","unstructured":"Costa RGF, et al. Cancer cachexia induces morphological and inflammatory changes in the intestinal mucosa. J Cachexia Sarcopenia Muscle. 2019;10(5):1116\u201327.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"967_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/jcsm.12053","volume":"7","author":"SM Ou","year":"2016","unstructured":"Ou SM, et al. Association of estimated glomerular filtration rate with all-cause and cardiovascular mortality: the role of malnutrition\u2013inflammation\u2013cachexia syndrome. J Cachexia Sarcopenia Muscle. 2016;7(2):144\u201351.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"967_CR43","doi-asserted-by":"publisher","first-page":"E700","DOI":"10.1210\/jc.2011-2387","volume":"97","author":"BO Burney","year":"2012","unstructured":"Burney BO, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab. 2012;97(5):E700\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"967_CR44","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s13539-012-0075-5","volume":"3","author":"AE Utech","year":"2012","unstructured":"Utech AE, et al. Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. J Cachexia Sarcopenia Muscle. 2012;3(4):245\u201351.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"2","key":"967_CR45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5005\/jp-journals-10011-1277","volume":"24","author":"P Singh","year":"2012","unstructured":"Singh P, et al. Evaluation of cachexia in oral submucous fibrosis. J Indian Acad Oral Med Radiol. 2012;24(2):130\u20132.","journal-title":"J Indian Acad Oral Med Radiol"},{"issue":"4","key":"967_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0885-3924(02)00508-0","volume":"24","author":"KA Nelson","year":"2002","unstructured":"Nelson KA, Walsh D. The cancer anorexia-cachexia syndrome: a survey of the prognostic inflammatory and nutritional index (PINI) in advanced disease. J Pain Symptom Manag. 2002;24(4):424\u20138.","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"967_CR47","first-page":"45","volume":"201","author":"H Persson","year":"1985","unstructured":"Persson H, et al. Thyroid hormones in conditions of chronic malnutrition: a study with special reference to cancer cachexia. Ann Surg. 1985;201(1):45\u201352.","journal-title":"Ann Surg"},{"issue":"4 SUPPL.","key":"967_CR48","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1097\/01.mcg.0000155514.17715.39","volume":"39","author":"M Chojkier","year":"2005","unstructured":"Chojkier M. Inhibition of albumin synthesis in chronic diseases: molecular mechanisms. J Clin Gastroenterol. 2005;39(4 SUPPL.):S143\u20136.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"967_CR49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1040-8428(97)00015-2","volume":"26","author":"G Stehle","year":"1997","unstructured":"Stehle G, et al. Plasma protein (albumin) catabolism by the tumor itself \u2013 implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol. 1997;26(2):77\u2013100.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"967_CR50","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/1097-0142(19801101)46:9<2041::AID-CNCR2820460923>3.0.CO;2-A","volume":"46","author":"WS Watson","year":"1980","unstructured":"Watson WS, Sammon AM. Body composition in cachexia resulting from malignant and non-malignant diseases. Cancer. 1980;46(9):2041\u20136.","journal-title":"Cancer"},{"issue":"3","key":"967_CR51","first-page":"669","volume":"35","author":"NF Dos Santos","year":"2018","unstructured":"Dos Santos NF, et al. Cachexia in hospitalized patients with heart failure. Nutr Hosp. 2018;35(3):669\u201376.","journal-title":"Nutr Hosp"},{"issue":"14","key":"967_CR52","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","volume":"35","author":"J Springer","year":"2014","unstructured":"Springer J, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J. 2014;35(14):932\u201341.","journal-title":"Eur Heart J"},{"key":"967_CR53","first-page":"S144","volume":"19","author":"T Kato","year":"2011","unstructured":"Kato T, et al. Cardiac cachexia is associated with abnormal liver metabolism and pro-inflammatory responses in a rat model of heart failure. Am Heart Assoc. 2011;19:S144.","journal-title":"Am Heart Assoc"},{"key":"967_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217841","author":"ME Rosa-Caldwell","year":"2020","unstructured":"Rosa-Caldwell ME, et al. Mitochondrial function and protein turnover in the diaphragm are altered in LLC tumor model of cancer cachexia. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21217841.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"967_CR55","first-page":"2912","volume":"41","author":"Y Kondo","year":"1981","unstructured":"Kondo Y, et al. Serum sialyltransferase and liver catalase activity in cachectic nude mice bearing a human malignant melanoma. Cancer Res. 1981;41(7):2912\u20136.","journal-title":"Cancer Res"},{"key":"967_CR56","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/metabo11120831","volume":"11","author":"N Miyaguti","year":"2021","unstructured":"Miyaguti N, et al. Walker-256 tumour-induced cachexia altered liver metabolomic profile and function in weanling and adult rats. Metabolites. 2021;11:831.","journal-title":"Metabolites"},{"issue":"2","key":"967_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/rco2.32","volume":"4","author":"AMM Castillo","year":"2021","unstructured":"Castillo AMM, et al. Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. JCSM Rapid Communications. 2021;4(2):232\u201344.","journal-title":"JCSM Rapid Communications"},{"key":"967_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250033","author":"HW Chen","year":"2021","unstructured":"Chen HW, et al. Impact of cachexia on oncologic outcomes of sarcopenic patients with upper tract urothelial carcinoma after radical nephroureterectomy. PLoS ONE. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0250033.","journal-title":"PLoS ONE"},{"key":"967_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.960341","volume":"10","author":"M Ferrara","year":"2022","unstructured":"Ferrara M, et al. Cancer cachexia as a multiorgan failure: reconstruction of the crime scene. Front Cell Dev Biol. 2022;10:960341.","journal-title":"Front Cell Dev Biol"},{"key":"967_CR60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-017-0727-z","volume":"77","author":"SA Schug","year":"2017","unstructured":"Schug SA, Ting S. Fentanyl formulations in the management of pain: an update. Drugs. 2017;77:747\u201363.","journal-title":"Drugs"},{"issue":"23","key":"967_CR61","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.3390\/cancers15235590","volume":"15","author":"CR Mariean","year":"2023","unstructured":"Mariean CR, et al. Cancer cachexia: new insights and future directions. Cancers. 2023;15(23):5590.","journal-title":"Cancers"},{"issue":"4","key":"967_CR62","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/medicina59040778","volume":"59","author":"WF Wong","year":"2023","unstructured":"Wong WF, et al. Recent advancement of medical patch for transdermal drug delivery. Medicina (B Aires). 2023;59(4):778.","journal-title":"Medicina (B Aires)"},{"key":"967_CR63","doi-asserted-by":"publisher","first-page":"508738","DOI":"10.3389\/fendo.2020.00025","volume":"11","author":"YP Silva","year":"2020","unstructured":"Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut\u2013brain communication. Front Endocrinol. 2020;11:508738.","journal-title":"Front Endocrinol"},{"issue":"1","key":"967_CR64","doi-asserted-by":"publisher","first-page":"1897212","DOI":"10.1080\/19490976.2021.1897212","volume":"13","author":"A Nogal","year":"2021","unstructured":"Nogal A, Valdes AM, Menni C. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. Gut microbes. 2021;13(1):1897212.","journal-title":"Gut microbes"},{"key":"967_CR65","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s42358-022-00240-9","volume":"62","author":"SS Maeda","year":"2022","unstructured":"Maeda SS, et al. Official position of the Brazilian Association of Bone Assessment and Metabolism (ABRASSO) on the evaluation of body composition by densitometry\u2014part II (clinical aspects): interpretation, reporting, and special situations. Adv Rheumatol. 2022;62:11.","journal-title":"Adv Rheumatol"},{"issue":"1","key":"967_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331.","journal-title":"Age Ageing"},{"issue":"1","key":"967_CR67","first-page":"15","volume":"14","author":"Y Rolland","year":"2011","unstructured":"Rolland Y, et al. Cachexia versus sarcopenia. Curr Opin Clin Nutr Metab Care. 2011;14(1):15\u201321.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"967_CR68","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99\u2013110.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"967_CR69","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1016\/j.bbagen.2013.05.005","volume":"1830","author":"K Yamasaki","year":"2013","unstructured":"Yamasaki K, et al. Albumin\u2013drug interaction and its clinical implication. Biochim Biophys Acta (BBA) Gen Subj. 2013;1830(12):5435\u201343.","journal-title":"Biochim Biophys Acta (BBA) Gen Subj"},{"key":"967_CR70","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3389\/fphar.2018.01283","volume":"9","author":"N Pavlovi\u0107","year":"2018","unstructured":"Pavlovi\u0107 N, et al. Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles. Front Pharmacol. 2018;9:1283.","journal-title":"Front Pharmacol"},{"issue":"8","key":"967_CR71","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.jsps.2019.09.011","volume":"27","author":"C Sun","year":"2019","unstructured":"Sun C, Chen L, Shen Z. Mechanisms of gastrointestinal microflora on drug metabolism in clinical practice. Saudi Pharm J. 2019;27(8):1146\u201356.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"967_CR72","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","volume":"9","author":"JS Fleishman","year":"2024","unstructured":"Fleishman JS, Kumar S. Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024;9(1):97.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"967_CR73","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/01635581.2024.2353939","volume":"76","author":"S Khan","year":"2024","unstructured":"Khan S, et al. A systematic review of cost-effectiveness analyses examining treatments for cachexia syndrome. Nutr Cancer. 2024;76(7):584\u201395.","journal-title":"Nutr Cancer"},{"issue":"1","key":"967_CR74","doi-asserted-by":"publisher","first-page":"263","DOI":"10.21037\/cdt-20-302","volume":"11","author":"RH Schwinger","year":"2021","unstructured":"Schwinger RH. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021;11(1):263.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"2","key":"967_CR75","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2008.11.103","volume":"133","author":"S Maraj","year":"2009","unstructured":"Maraj S, Pressman GS, Figueredo VM. Primary cardiac tumors. Int J Cardiol. 2009;133(2):152\u20136.","journal-title":"Int J Cardiol"},{"issue":"4","key":"967_CR76","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1002\/jcsm.13260","volume":"14","author":"M Okamura","year":"2023","unstructured":"Okamura M, et al. Kidney function in cachexia and sarcopenia: facts and numbers. J Cachexia Sarcopenia Muscle. 2023;14(4):1589\u201395.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"5","key":"967_CR77","first-page":"482","volume":"26","author":"IM Rocha","year":"2023","unstructured":"Rocha IM, et al. Understanding the gut microbiota in cancer cachexia. Curr Opin Clin Nutr Metab Care. 2023;26(5):482\u20139.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"4","key":"967_CR78","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.smhs.2020.10.003","volume":"2","author":"S Lim","year":"2020","unstructured":"Lim S, et al. Development and progression of cancer cachexia: perspectives from bench to bedside. Sports Med Health Sci. 2020;2(4):177\u201385.","journal-title":"Sports Med Health Sci"},{"issue":"2","key":"967_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188359","volume":"1873","author":"JA Siddiqui","year":"2020","unstructured":"Siddiqui JA, et al. Advances in cancer cachexia: intersection between affected organs, mediators, and pharmacological interventions. Biochim Biophys Acta (BBA) Rev Cancer. 2020;1873(2):188359.","journal-title":"Biochim Biophys Acta (BBA) Rev Cancer"},{"issue":"12","key":"967_CR80","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","volume":"4","author":"SF Schmidt","year":"2018","unstructured":"Schmidt SF, et al. Cancer cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4(12):849\u201360.","journal-title":"Trends Cancer"},{"issue":"11","key":"967_CR81","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s00467-010-1733-5","volume":"26","author":"WW Cheung","year":"2011","unstructured":"Cheung WW, et al. The impact of inflammation on bone mass in children. Pediatr Nephrol. 2011;26(11):1937\u201346.","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"967_CR82","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00467-009-1427-z","volume":"25","author":"WW Cheung","year":"2010","unstructured":"Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in chronic kidney disease. Pediatr Nephrol. 2010;25(4):711\u201324.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"967_CR83","first-page":"72","volume":"52","author":"A Inui","year":"2002","unstructured":"Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clinicians. 2002;52(2):72\u201391.","journal-title":"CA Cancer J Clinicians"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00967-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00967-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:09:00Z","timestamp":1761127740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00967-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00967-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}